A detailed history of Voya Investment Management LLC transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Voya Investment Management LLC holds 20,545 shares of VTYX stock, worth $46,637. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,545
Previous 72,179 71.54%
Holding current value
$46,637
Previous $166,000 73.49%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.85 - $3.2 $95,522 - $165,228
-51,634 Reduced 71.54%
20,545 $44,000
Q2 2024

Dec 03, 2024

BUY
$2.31 - $5.59 $119,274 - $288,634
51,634 Added 251.32%
72,179 $166,000
Q2 2024

Aug 14, 2024

SELL
$2.31 - $5.59 $90,066 - $217,954
-38,990 Reduced 35.07%
72,179 $166,000
Q1 2024

Dec 06, 2024

BUY
$1.9 - $10.13 $172,185 - $918,021
90,624 Added 441.1%
111,169 $611,000
Q1 2024

May 15, 2024

BUY
$1.9 - $10.13 $175,212 - $934,158
92,217 Added 486.58%
111,169 $611,000
Q4 2023

Feb 14, 2024

SELL
$2.08 - $31.18 $180,311 - $2.7 Million
-86,688 Reduced 82.06%
18,952 $46,000
Q3 2023

Nov 14, 2023

SELL
$29.8 - $40.3 $763,029 - $1.03 Million
-25,605 Reduced 19.51%
105,640 $3.67 Million
Q2 2023

Aug 14, 2023

BUY
$28.53 - $39.55 $3.48 Million - $4.82 Million
121,896 Added 1303.84%
131,245 $4.3 Million
Q4 2022

Feb 14, 2023

BUY
$24.16 - $36.38 $13,602 - $20,481
563 Added 6.41%
9,349 $306,000
Q3 2022

Mar 03, 2023

SELL
$12.64 - $38.7 $7,116 - $21,788
-563 Reduced 6.02%
8,786 $306,000
Q3 2022

Nov 14, 2022

BUY
$12.64 - $38.7 $111,055 - $340,018
8,786 New
8,786 $307,000

Others Institutions Holding VTYX

About Ventyx Biosciences, Inc.


  • Ticker VTYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,527,200
  • Market Cap $128M
  • Description
  • Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...
More about VTYX
Track This Portfolio

Track Voya Investment Management LLC Portfolio

Follow Voya Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.